title: Serological immune response to cancer testis antigens in patients with pancreatic cancer.
abstract: Serological screening approaches have allowed for the identification of a large number of potentially relevant tumor antigens in cancer patients. Within this group, cancer testis antigens represent promising targets for cancer immunotherapy, since they are widely expressed in a variety of human cancer entities. In pancreatic cancer, however, there are only few data available about the expression pattern and serological response to cancer testis antigens and other serological-defined tumor antigens. Therefore, we investigated the IgG antibody response against 11 cancer testis antigens (SCP-1, GAGE, LAGE-1a,-1b, CT-7, NY-ESO-1, SSX-1-5) recombinantly expressed on yeast surface (RAYS) in patients with pancreatic cancer (n = 96), chronic pancreatitis (n = 18) and healthy donors (n = 48). We found in 14% of all patients antibody responses to SCP-1, but not to other cancer testis antigens (GAGE, LAGE-1a,-1b, CT-7, NY-ESO-1, SSX-1-5). Antibody response correlated with the expression of SCP-1 in the primary tumor of the respective patient as shown by RT-PCR, immunohistochemistry and Western blot. In contrast, no serological response to cancer testis antigens was observed in healthy donors. The humoral immune response against SCP-1 was associated with the size of tumor, but not with other clinico-pathological parameters such as histology, stage, presence of lymph node metastases, grading, age, gender or gemcitabine treatment. In conclusion, antibody response to cancer testis antigen SCP-1 is found in a proportion of pancreatic carcinoma patients. These results indicate that identification of additional tumor antigens by serological screening of tumor cDNA expression libraries by RAYS is a promising goal in pancreatic cancer.
authors.affiliation: Department of Internal Medicine I, University of Saarland Medical School, Homburg/Saar, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Wadle
authors.forename: Boris
authors.initials: B
authors.lastname: Kubuschok
authors.forename: Jochen
authors.initials: J
authors.lastname: Imig
authors.forename: Beate
authors.initials: B
authors.lastname: Wuellner
authors.forename: Christine
authors.initials: C
authors.lastname: Wittig
authors.forename: Carsten
authors.initials: C
authors.lastname: Zwick
authors.forename: Axel
authors.initials: A
authors.lastname: Mischo
authors.forename: Kristin
authors.initials: K
authors.lastname: Waetzig
authors.forename: Bernd F M
authors.initials: BF
authors.lastname: Romeike
authors.forename: Werner
authors.initials: W
authors.lastname: Lindemann
authors.forename: Martin
authors.initials: M
authors.lastname: Schilling
authors.forename: Michael
authors.initials: M
authors.lastname: Pfreundschuh
authors.forename: Christoph
authors.initials: C
authors.lastname: Renner
mesh_terms: D000368:Aged; D000951:Antigens, Neoplasm / Q000276:immunology*; D014408:Biomarkers, Tumor / Q000276:immunology*; D015153:Blotting, Western; D045744:Cell Line, Tumor; D005260:Female; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008565:Membrane Proteins / Q000276:immunology*; D008875:Middle Aged; D009687:Nuclear Proteins; D010190:Pancreatic Neoplasms / Q000276:immunology*; D010749:Phosphoprotein Phosphatases / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013737:Testis
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C104948:CTAG1B protein, human; D008565:Membrane Proteins; D009687:Nuclear Proteins; C413483:CTDSP1 protein, human; D010749:Phosphoprotein Phosphatases